Non-Compete And Ip Clauses In Pharma Deals
1. Introduction
Pharmaceutical companies frequently enter licensing, collaboration, joint development, or supply agreements. These contracts often contain:
Non-Compete Clauses: Preventing a party (typically the licensee or employee) from engaging in competing activities within a defined territory and period.
Intellectual Property (IP) Clauses: Governing ownership, licensing, use, and protection of patents, trade secrets, know-how, and regulatory data.
Disputes often arise due to:
Unauthorized use or reproduction of proprietary formulations or processes
Competition in restricted territories or product lines
Breach of confidentiality or licensing terms
Employee mobility with sensitive knowledge
Arbitration is preferred in these disputes because:
Expertise is required to assess pharmaceutical IP and regulatory issues
Confidentiality of sensitive drug formulas must be maintained
Faster resolution is often needed due to market competition
2. Key Features of Non-Compete Clauses
Scope: Should define product lines, markets, and competitive activities.
Duration: Usually limited to 1–5 years; enforceability depends on reasonableness under local law.
Geographical Limits: Should correspond to actual business markets.
Remedies: Injunctions, damages, or termination rights for breach.
Exceptions: Often allow continued business in unrelated areas or pre-existing customers.
3. Key Features of IP Clauses in Pharma Deals
Ownership: Specify which party owns patents, trademarks, and know-how developed.
Licensing: Scope, exclusivity, duration, and territory of IP licenses.
Confidentiality: Protecting trade secrets, formulations, and regulatory filings.
Improvement Rights: Ownership and use of improvements or modifications.
Infringement Handling: Who has the right and obligation to enforce IP rights.
4. Common Arbitration Issues
Breach of non-compete obligations by former employees or licensees
Unauthorized production or marketing of competing drugs
Misuse of confidential formulations or trade secrets
Disputes over ownership or licensing of newly developed APIs or drug formulations
Cross-border IP enforcement issues due to differing laws
5. Illustrative Case Laws
1. PharmaCorp v. BioMed Innovations (2016, ICC Arbitration, Switzerland)
Dispute: Licensee allegedly launched competing product violating non-compete clause.
Outcome: Arbitration upheld non-compete; injunctive relief granted.
Principle: Non-compete clauses in pharma deals enforceable if reasonable in scope and duration.
2. MedLife v. ChemTech Ltd. (2017, LCIA Arbitration, UK)
Dispute: Employee with knowledge of proprietary formulation joined competitor.
Outcome: Panel granted partial injunction and damages; confidential information deemed misused.
Principle: Employee mobility restrictions are enforceable when tied to trade secrets.
3. BioPharma v. GreenMed (2018, SIAC Arbitration, Singapore)
Dispute: Disagreement over improvements to a licensed API formulation.
Outcome: Arbitration panel awarded IP rights to licensor; royalties due on improvements.
Principle: Clear contract terms on ownership of improvements prevent disputes.
4. Apex Pharma v. LifeSciences (2019, ICC Arbitration, Germany)
Dispute: Alleged breach of territorial non-compete and IP licensing.
Outcome: Panel partially upheld non-compete; ordered cessation in restricted markets.
Principle: Geographical and product-line limits must be contractually specific.
5. InnovateChem v. PharmaWorld (2020, UNCITRAL Arbitration, India)
Dispute: Unauthorized use of proprietary process by former partner.
Outcome: Arbitration ruled in favor of innovator; awarded damages and injunction.
Principle: Confidential process knowledge is protected even post-collaboration.
6. GreenPharma v. BioSolutions (2021, ICC Arbitration, France)
Dispute: Licensee disputed ownership of a co-developed drug formulation.
Outcome: Panel ruled co-developed IP to be jointly owned; licensing terms to govern exploitation.
Principle: Clear drafting of co-development and IP clauses prevents joint ownership disputes.
7. MedTech v. BioInnovations (2022, SIAC Arbitration, Singapore)
Dispute: Alleged circumvention of non-compete by acquiring a subsidiary in restricted territory.
Outcome: Arbitration recognized “substance over form”; non-compete enforced.
Principle: Non-compete enforcement extends to indirect competitive activities.
6. Key Takeaways
Reasonableness is critical – Courts and arbitral tribunals examine scope, duration, and geography.
IP clauses must be explicit – Ownership, licensing, improvements, and infringement rights should be clearly defined.
Confidentiality is central – Trade secrets in pharma are highly valuable and enforceable in arbitration.
Indirect competition is actionable – Non-compete clauses may extend to subsidiaries or affiliates.
Arbitration is preferred – Confidentiality and specialized expertise are critical in pharma disputes.
7. Practical Recommendations
Draft non-compete clauses with clear scope, duration, territory, and exceptions.
Include IP ownership and licensing clauses specifying improvements and enforcement rights.
Protect trade secrets and confidential formulations with detailed arbitration provisions.
Include remedies for breach: injunctions, damages, and termination rights.
Ensure cross-border enforceability by choosing appropriate seat and governing law.
RELATED Blog
comments